Why this matters now
Increasing numbers of veterans are considering medical cannabis as a solution to chronic pain, sleep, and trauma-related symptoms. The public-health agencies estimate that about 3 out of every 10 individuals who consume cannabis will use the drug at some point to satisfy the criteria of CUD, and the sooner it starts, and the greater the consumption, the more it increases the risk. This is essential because veterans are vulnerable to chronic pain and PTSD, which already puts a significant burden on them, and it is important to find the right balance between the possible benefits and risks. (CDC)
Two things are clear in the Department of Veterans Affairs: veterans won’t lose VA benefits because of cannabis use, and veterans are urged to discuss it frankly with their VA care team. Meanwhile, the 2023 VA/DoD guideline on PTSD does not specifically suggest the use of cannabis to treat the symptoms of PTSD because of the lack of evidence on efficacy and risks. (Public Health VA)
Quick primer: What is cannabis use disorder?
CUD diagnosis is based on DSM-5. Symptoms that the veteran (and family) tend to be aware of include: not being able to reduce use, increasing tolerance to THC, taking it to alleviate anxiety/sleep, missing commitments, or using it despite deteriorating mood, cognitive, or physical state. (NCBI)
Risk is not spread out evenly. Higher CUD rates have been associated with earlier onset, daily or high-potency THC preparations, comorbid mental disorders, as well as a history of trauma. In the population statistics, the proportion of individuals consuming cannabis on a daily or almost daily basis has increased. (AP News)
Evidence check: what cannabis helps—and where data are thin.
A landmark National Academies report concluded there’s conclusive or substantial evidence that cannabis or cannabinoids help chronic pain in adults, chemotherapy-induced nausea and vomiting (with oral cannabinoids), and patient-reported MS spasticity, but did not find strong evidence for PTSD treatment. (National Academies Press)
Small randomized work with nabilone suggests it can reduce trauma-related nightmares for some military patients, promising but not definitive. The field needs larger, modern trials that reflect today’s products and potencies. (PubMed)
The DNA angle: why genetics may change your cannabis experience
Genetics influence who uses cannabis, who develops CUD, and how individuals respond:
- Heritability: Twin and genomic studies indicate that problematic cannabis use is moderately heritable. (Nature)
- Specific genes: A 2019 genome-wide association study linked CHRNA2 with CUD risk. (PMC)
- Metabolism genes: CYP2C9 variants (especially *2/*3 alleles) can slow THC breakdown, raising plasma THC and potentially side effects at “standard” doses—especially with oral products. (ASCPT Journal)
- Endocannabinoid tone: Variants in FAAH and CNR1 have been associated with differences in fear learning, anxiety traits, and, variably across studies, PTSD risk. (ScienceDirect)
Bottom line: DNA won’t “decide your fate,” but it helps explain why cannabis feels calming to one veteran and dysregulating to another. (PMC)
PTSD, the endocannabinoid system, and what’s plausible
The endocannabinoid system (ECS) modulates fear learning, memory reconsolidation, threat detection, sleep, and core PTSD domains. Preclinical and human imaging data suggest altered ECS signaling in PTSD. (Nature)
That’s why trauma-focused psychotherapies (e.g., Prolonged Exposure, Cognitive Processing Therapy, EMDR) and first-line medications remain the backbone of evidence-based PTSD care in the VA/DoD guideline, with cannabis not recommended as a PTSD treatment. If a veteran chooses to use cannabis for symptom relief, it should complement, not replace, proven therapies. (PTSD.gov)
If you’re a veteran using—or considering—medical cannabis.
- Talk to your VA team. You won’t lose benefits for disclosing cannabis use. Documenting products, frequency, and effects helps your clinicians monitor interactions, cognition, mood, and sleep, and spot early signs of CUD. (Public Health VA)
- Align goals with evidence. If your primary aim is chronic pain or chemotherapy-related nausea, evidence is more substantial. If the target is PTSD, set cautious expectations and build a parallel plan for gold-standard treatments. (National Academies Press)
- Reduce foreseeable risk. Practical harm-reduction steps include:
- Prefer lower-THC or balanced THC: CBD formulations.
- Start low, go slow—especially with edibles, and if you might carry a **CYP2C92/3 variant. (ASCPT Journal)
- Don’t mix with benzodiazepines, alcohol, or sedative-hypnotics without a clinician’s input.
- Protect sleep and daytime functioning.
- Keep an eye on CUD signals. If you’re using more than intended or noticing mood/cognition worsening, bring it up—early. (NCBI)
If you suspect cannabis use disorder, what helps?
There are no FDA-approved medications for CUD yet. But behavioral treatments work:
Contingency management (CM)—Structured rewards for negative drug screens; strongest evidence for reducing or stopping use. Widely implemented in VA SUD clinics. (PMC)
Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET) reduce use and related problems. Though gains can fade without ongoing support. Group formats and digital adjuncts are expanding access. (PMC)
Combining CM with CBT/MET can be especially practical in VA settings. Where urine monitoring and structured rewards are feasible. (SpringerLink)
Veterans can access SUD services through VA mental health. Ask about programs that integrate trauma care with SUD treatment. (mentalhealth.va.gov)
Coordinating VA care with state-legal medical cannabis
Because cannabis is federally illegal, VA clinicians cannot recommend or prescribe it. However, they can discuss your use, document it, and adjust your care. Enrollment in a state cannabis program does not affect your VA services or benefits.
A good workflow looks like this:
- Share your cannabis regimen (product type, THC/CBD ratio, route, dose, timing)with your VA primary care and mental health providers.
- Ask about drug–drug interactions and safe-driving advice.
- If pursuing trauma-focused therapy, work with your therapist on timing cannabis use. (Public Health VA)
DNA-aware, veteran-first: what “precision cannabis care” could look like
We’re not prescribing by genotype today, but a forward-looking system for veterans might include:
Metabolic caution flags: In oral THC use, note potential CYP2C9 poor metabolizers who may need ultra-low starting doses. (ASCPT Journal)
Risk profiling for CUD: Polygenic risk scores are still research-only but may eventually guide closer monitoring. (PMC)
ECS-targeted adjuncts: As evidence grows, cannabinoid therapies may serve as short-term adjuncts for certain PTSD symptom clusters. (PubMed)
Until then, the safest “precision” is behavioral precision: clear goals, careful product selection, slow titration, routine check-ins, and fast responses to early warning signs of CUD.
A veteran’s checklist for safer, more innovative use
- Set a goal (nightmares, sleep onset, neuropathic pain) and pick a measure (sleep diary, PCL-5, pain scale).
- Start low, go slow, especially with edibles; wait a few days before increasing. If anxiety or fogginess appears, lower THC or raise CBD. (NCBI)
- Protect therapy: Avoid use before trauma-focused sessions unless your therapist approves. (PTSD.gov)
- Take tolerance breaks; if they’re hard to maintain, ask about CUD screening. (NCBI)
- Avoid mixing with sedatives/alcohol; check interactions.
- Never drive impaired.
- Loop in your VA team. You won’t be penalized for honest disclosure. (Public Health VA)
The path forward
For many veterans, cannabis is here—used with hopes of easing pain, improving sleep, or steadying a nervous system wired by trauma. Science is catching up. We already know enough to reduce harm, detect CUD early, and center PTSD treatments that work. We can also acknowledge biology: genes shape response and risk. As research matures—from CYP2C9 metabolism to CHRNA2 and ECS targets—precision-minded, veteran-first frameworks will help the right patient, with the right product, at the correct dose, for the right reason.
For now, the best approach is coordinated care among you, your VA clinicians, and your state cannabis provider—aligned on your goals, safety, and long-term well-being.
Key references
- VA policy on veterans and marijuana use; VA mental health page on CUD; VA/DoD PTSD guideline & PTSD-cannabis brief. (Public Health VA)
- National Academies (2017) conclusions on therapeutic effects. (National Academies Press)
- DSM-5 overview and clinical features of CUD. (NCBI)
- Public-health estimates of CUD prevalence among users. (CDC)
- Genetics and metabolism: CHRNA2 GWAS; CYP2C9 and THC metabolism; FAAH/CNR1 in stress/PTSD. (PMC)
CUD treatments: contingency management, CBT/MET, and VA implementation. (PubMed)
IMPORTANT NOTICE
Educational use only. No medical or legal advice.
Mendry is a 501(c)(3) nonprofit, not a government agency, and not affiliated with the VA or any federal or state agency.
Mendry does not provide treatment, prescribe or sell cannabis, or collect PHI.
Healthcare decisions are yours and your licensed clinicians’ only.
Emergency: 911 | Veterans Crisis Line: 988 (Press 1)